In conclusion, data of this report revealed that treatment with 5HT2A antagonist improves the survival rate and ameliorates pain threshold in pancreatic cancer mice, as it significantly reduces the level of inflammatory cytokines and mRNA expression of HDAC inhibition and inflammatory cytokines. Here, HTR2A is linked to familial pancreatic carcinoma.